Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Zhiming Li, Hang Yang, Yanxue Yin, Yajun Li, Xue Gao, Peng Sun, Yu Wang, Lu Zhang, Hui Zhou, Keshu Zhou, Jay Mei

Blood (2023) 142 (Supplement 1): 6240.

https://doi.org/10.1182/blood-2023-181503

Published: 2023

Journal Articles

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Lu Zhang, Bill Poland, Shuang Xu, Martine Allard, Cecile Krejsa, J. Greg Slatter

Blood (2023) 142 (Supplement 1): 5755.

https://doi.org/10.1182/blood-2023-174749

Published: 2023

Journal Articles

Histone Methyltranferase SETD8 Stimulates Proliferation and Anti-Apoptotic Effect in Acute Myeloid Leukemia through Epigenetically Upregulation of CXCR4

Zelong Cui, Man Xu, Zhenxing Gao, Minran Zhou, Yue Fu, Huimin Feng, Lu Zhang, Chunyan Chen

Blood (2023) 142 (Supplement 1): 2754.

https://doi.org/10.1182/blood-2023-184524

Published: 2023

Journal Articles

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

Qi Zhang, He Li, Xuelan Chen, Fan Gu, Lanxin Zhang, Lu Zhang, Tong Chen, Qiang Chen, Wentong Meng, Yu Wu, Hong Chang, Ting Liu, Chong Chen, Hongbing Ma, Yu Liu

Blood (2023) 142 (17): 1494–1499.

https://doi.org/10.1182/blood.2023020619

Published: 2023

Includes: Supplemental data

Journal Articles

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

Hao Zhao, Miao-yan Zhang, Kai-ni Shen, Jun Feng, Xin-xin Cao, Ming-hui Duan, Dao-bin Zhou, Lu Zhang, Jian Li

Blood (2023) 141 (21): 2654–2657.

https://doi.org/10.1182/blood.2023020009

Published: 2023

Includes: Supplemental data

Journal Articles

Maintenance Therapy with Single-Agent Lenalidomide for POEMS Syndrome

Yanying Yu, Xuemin Gao, Hao Zhao, Anan Li, Hao Cai, Jun Feng, Lu Zhang, Xinxin Cao, Jian Li

Blood (2022) 140 (Supplement 1): 10118–10119.

https://doi.org/10.1182/blood-2022-158642

Published: 2022

Journal Articles

LRG1, a Novel Serum Biomarker for Idiopathic Multicentric Castleman Disease Activity

Miaoyan Zhang, Yan-Ying Yu, Xin-xin Cao, Dao-Bin Zhou, Jian Li, Lu Zhang

Blood (2022) 140 (Supplement 1): 11923–11924.

https://doi.org/10.1182/blood-2022-156572

Published: 2022

Journal Articles

A Prospective Study of Bortezomib, Cyclophosphamide and Dexamethasone in Newly-Diagnosed Idiopathic Multicentric Castleman's Disease

Hao Zhao, Miaoyan Zhang, Yanying Yu, Xinxin Cao, Dao-Bin Zhou, Lu Zhang, Jian Li

Blood (2022) 140 (Supplement 1): 4442–4443.

https://doi.org/10.1182/blood-2022-166349

Published: 2022

Journal Articles

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Yan Zhang, Wei Wang, Jian Li, Daobin Zhou, Wei Zhang, Danqing Zhao, Chong Wei, Lu Zhang, Xinxin Cao

Blood (2022) 140 (Supplement 1): 6608–6609.

https://doi.org/10.1182/blood-2022-165934

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Patients with Mayo 2004 Stage 3 Light-Chain Amyloidosis: A Prospective Phase 2 Study

Ya-Juan Gao, Kaini Shen, Long Chang, Jun Feng, Yueying Mao, Lu Zhang, Xinxin Cao, Daobin Zhou, Jian Li

Blood (2022) 140 (Supplement 1): 4391–4392.

https://doi.org/10.1182/blood-2022-157044

Published: 2022

Journal Articles

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Blood (2022) 140 (Supplement 1): 3609–3611.

https://doi.org/10.1182/blood-2022-158675

Published: 2022

Journal Articles

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data

Caixia Li, Jia Wei, Keshu Zhou, Peng Liu, He Huang, Fei Li, Yujun Dong, Qingqing Cai, Shenmiao Yang, Xinyou Zhang, Hui Zhou, Lu Zhang, Zaixing Shi, Zhiyu Liang, Binghao Wu, Depei Wu

Blood (2022) 140 (Supplement 1): 6717–6718.

https://doi.org/10.1182/blood-2022-171046

Published: 2022

Journal Articles

The Interim Analysis from a Prospective Single-Center Phase 2 Study of Zanubrutinib Plus R-CHOP in Treat-Naïve Intravascular Large B Cell Lymphoma

Yan Zhang, Congwei Jia, Wei Wang, Lu Zhang, Xinxin Cao, Jian Li, Wei Zhang, Daobin Zhou

Blood (2021) 138 (Supplement 1): 3563.

https://doi.org/10.1182/blood-2021-152417

Published: 2021

Journal Articles

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1830.

https://doi.org/10.1182/blood-2021-150037

Published: 2021

Journal Articles

An Enterohepatic Recirculation Population Pharmacokinetic and MIC-1 Pharmacokinetic-Pharmacodynamic Model for the MDM2 Inhibitor Navtemadlin (KRT-232) in Healthy Subjects

Lu Zhang, Bill Poland, Michelle Green, Shekman Wong, J. Greg Slatter

Blood (2021) 138 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2021-145205

Published: 2021

Journal Articles

Unicentric Castleman Disease with High Inflammatory State: Surgical Treatment Is a Potential Cure

Miaoyan Zhang, Xinxin Cao, MD, Dao-Bin Zhou, Lu Zhang, MD, Jian Li, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-134350

Published: 2020

Journal Articles

Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis

Xinxin Cao, MD, Ming-hui Duan, MD, Ai-lin Zhao, Hao Cai, Jia Chen, Xue-min Gao, Ting Liu, Hua-cong Cai, MD, Lu Zhang, Jian Sun, MD, Zhi-yong Liang, MD, Dao-Bin Zhou, Jian Li, MD

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-138426

Published: 2020

Journal Articles

A Prospective, Multicenter Study of Bortezomib, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Idiopathic Multicentric Castleman's Disease

Lu Zhang, MD, Ming-nan Jia, MD, Ai-lin Zhao, MD, Jun Feng, MD, Xin-xin Cao, MD, Yan Zhang, MD, Ming-hui Duan, MD, Dao-Bin Zhou, Yujun Dong, MD, Jian Li, MD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-140115

Published: 2020

Journal Articles

A Highly Heterogeneous Mutational Pattern in POEMS Syndrome

Jia Chen, Xue-min Gao, Hao Zhao, MD, Hao Cai, Lu Zhang, MD, Xin-xin Cao, MD, Dao-Bin Zhou, Jian Li, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-134900

Published: 2020

Journal Articles

Impact of Hematologists' Personality and Behavioral Traits on Medical Decision-Making for Elderly Acute Myeloid Leukemia: A National Study in China

Xia Wu, MD, Yi-Nan Jiang, Yue-Lun Zhang, Jia Chen, Yue-ying Mao, Lu Zhang, MD, Dao-Bin Zhou, Xinxin Cao, MD, Jian Li, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-135957

Published: 2020

NARROW

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Histone Methyltranferase SETD8 Stimulates Proliferation and Anti-Apoptotic Effect in Acute Myeloid Leukemia through Epigenetically Upregulation of CXCR4

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

Maintenance Therapy with Single-Agent Lenalidomide for POEMS Syndrome

LRG1, a Novel Serum Biomarker for Idiopathic Multicentric Castleman Disease Activity

A Prospective Study of Bortezomib, Cyclophosphamide and Dexamethasone in Newly-Diagnosed Idiopathic Multicentric Castleman's Disease

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Patients with Mayo 2004 Stage 3 Light-Chain Amyloidosis: A Prospective Phase 2 Study

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data

The Interim Analysis from a Prospective Single-Center Phase 2 Study of Zanubrutinib Plus R-CHOP in Treat-Naïve Intravascular Large B Cell Lymphoma

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

An Enterohepatic Recirculation Population Pharmacokinetic and MIC-1 Pharmacokinetic-Pharmacodynamic Model for the MDM2 Inhibitor Navtemadlin (KRT-232) in Healthy Subjects

Unicentric Castleman Disease with High Inflammatory State: Surgical Treatment Is a Potential Cure

Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis

A Prospective, Multicenter Study of Bortezomib, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Idiopathic Multicentric Castleman's Disease

A Highly Heterogeneous Mutational Pattern in POEMS Syndrome

Impact of Hematologists' Personality and Behavioral Traits on Medical Decision-Making for Elderly Acute Myeloid Leukemia: A National Study in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only